Company Profile
Altimmune Stock Price, News & Analysis
- Ticker:
- ALT
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
3.01 USD (-0.66%)
Close
Last updated: August 6, 2026
564M USD
Market cap
Why the stock is moving
The latest company update was “Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026”. ALT changed 1.30% and closed at $3.03 on Aug 5, 2026, indicating a relatively limited closing-price reaction to this earnings update.
Company overview
Metabolic and Liver Disease Company
Altimmune develops pemvidutide for serious metabolic and liver diseases.
Balanced Dual Agonist
Pemvidutide is a balanced glucagon and GLP-1 receptor agonist intended to combine weight loss with direct effects on liver fat, inflammation, and lipid metabolism.
MASH Program
The global PERFORMA program is designed to evaluate pemvidutide as a Phase 3 treatment for metabolic dysfunction-associated steatohepatitis.
Alcohol-Related Disease
The RECLAIM study evaluates pemvidutide in alcohol use disorder, with potential expansion into alcohol-associated liver disease.
Future catalysts
The Phase 3 PERFORMA study in MASH is expected to begin in the second half of 2026.
Topline data from the Phase 2 RECLAIM trial in alcohol use disorder are expected in the third quarter of 2026.
A 52-week PERFORMA data readout is anticipated in 2029.
Recent news
- 01
- 02
- 03
- 04
- 05
Altimmune to Participate in Upcoming Investor Conferences
Source: Altimmune
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Altimmune (ALT)?
Altimmune (ALT) most recently closed at 3.01 USD, a -0.66% move versus the previous session.
What is the market cap of Altimmune (ALT)?
Altimmune currently has a market capitalization of 564M USD on BioPharmSignal.
What does Altimmune do?
Metabolic and Liver Disease Company Altimmune develops pemvidutide for serious metabolic and liver diseases. Balanced Dual Agonist Pemvidutide is a balanced glucagon and GLP-1 receptor agonist intended to combine weight loss with direct effects on liver fat, inflammation, and lipid metabolism. MASH Program The global PERFORMA program is designed to evaluate...
On which exchange is ALT stock listed?
Altimmune (ALT) is associated with NASDAQ, United States, Biopharma.
What is GLP-1?
Balanced Dual Agonist Pemvidutide is a balanced glucagon and GLP-1 receptor agonist intended to combine weight loss with direct effects on liver fat, inflammation, and lipid metabolism.
Which conditions is Altimmune targeting with GLP-1?
Altimmune is associated with inflammatory disease, metabolic disease based on its company overview and current catalyst commentary.
How does Altimmune describe recent progress with GLP-1?
The Phase 3 PERFORMA study in MASH is expected to begin in the second half of 2026. Topline data from the Phase 2 RECLAIM trial in alcohol use disorder are expected in the third quarter of 2026. A 52-week PERFORMA data readout is anticipated in 2029.
What is Metabolic?
Metabolic and Liver Disease Company Altimmune develops pemvidutide for serious metabolic and liver diseases.